Cancer News and Research

Latest Cancer News and Research

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Cyclacel Pharmaceuticals, Inc. announced today that updated Phase 2 clinical trial results of sapacitabine for the treatment of myelodysplastic syndromes (MDS) will be presented at a poster presentation during the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, on Saturday, December 4, 2010.

19 Nov 2010

Cold Spring releases new series of laboratory manuals

Sophisticated techniques that permit the visualization of dynamic processes in cells, tissues, and organ systems at extraordinary levels of resolution have become tremendously valuable in biological research. However, finding the right imaging method and optimizing it for data collection can be a daunting process, even for an established imaging laboratory. To fill this need, a new series of laboratory manuals has been developed by Cold Spring Harbor Laboratory Press. The first volume in this series, Imaging: A Laboratory Manual, has just been released.

19 Nov 2010

Substance abuse treatment facilities offering nicotine replacement therapy increased by 6%: Report

The percentage of substance abuse treatment facilities offering nicotine replacement therapy to clients gradually increased by about 6 percentage points from 2006 to 2009, according to a new Spotlight report issued by the Substance Abuse and Mental Health Services Administration released in conjunction with the "Great American Smokeout."

19 Nov 2010

AVEO's RON antibody shows anti-tumor activity in human cancer xenografts

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data from AVEO's anti-RON antibody program which demonstrated the successful identification of antibodies with potent anti-tumor activity that demonstrated inhibition of the function of both wild type RON and the RONΔ160 variant, as well as a potential biomarker to identify tumors likely to respond to treatment with the anti-RON antibody.

19 Nov 2010

Fifth gene defect, 47 DNA regions linked to thoracic aortic disease: Researchers

Discovery of a fifth gene defect and the identification of 47 DNA regions linked to thoracic aortic disease are the subject of studies released this month involving researchers at The University of Texas Health Science Center at Houston.

19 Nov 2010

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ZIOPHARM Oncology, Inc. announced today important new preclinical data on the efficacy of darinaparsin (ZinaparTM, or ZIO-101) in various solid tumor models delivered at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany.

19 Nov 2010

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products using its Targeted Antibody Payload (TAP) technology, today announced the presentation of encouraging clinical data for the Company's IMGN388 anticancer compound at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany.

19 Nov 2010

Research suggests new therapeutic approach to prevent transplant rejection

UCLA researchers have pinpointed the culprit behind chronic rejection of heart, lung and kidney transplants. Published in the Nov. 23 edition of Science Signaling, their findings suggest new therapeutic approaches for preventing transplant rejection and sabotaging cancer growth.

19 Nov 2010

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Cough medicine could be used as way of predicting how well individual patients metabolise tamoxifen used in the treatment of their breast cancer, according to new research presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin today

19 Nov 2010

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place in Berlin, Germany from November 16 to19, 2010.

19 Nov 2010

ACE-041 drug may provide new option to treat cancer

Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.

19 Nov 2010

Personalised medicine could help develop effective treatments for serious diseases

Personalised medicine is a field that holds a lot of promise as a provider of practices and technology that could help develop more effective treatments for serious diseases such as cancer. Personalised medicine involves tailoring treatment according to the genetic profile and molecular makeup of each patient.

19 Nov 2010

DoD recommends funding for Synta's STA-9584 for prostate cancer study

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Department of Defense (DoD) has recommended STA-9584, a novel vascular disrupting agent (VDA) currently in pre-clinical development at Synta, be funded for study in advanced prostate cancer.

19 Nov 2010

International businessman donates $50,000 for SCCO cancer study

International businessman and philanthropist Foster Friess has donated $50,000 to help launch a study of small cell carcinoma of the ovary (SCCO) by the Translational Genomics Research Institute (TGen) and the Van Andel Research Institute (VARI).

19 Nov 2010

Caprini Risk Model helps predict VTE risk in patients undergoing plastic surgery

Patients undergoing plastic or reconstructive surgery should receive a risk assessment before their procedure to predict whether they'll develop potentially fatal blood clots in the legs or lungs, according to research at the University of Michigan Medical School. Researchers also found that 1 in 9 patients at highest risk based on that assessment will develop clots if not given clot-preventing medications after surgery.

19 Nov 2010

CNS-ASU book explores relationship between nanotechnology and equity

Scientists and policymakers both contend that investments in nanoscale science and engineering will create revolutions in areas as diverse as materials, drug delivery, cancer treatment, and space travel. The hope is that many of the problems of today can be addressed using nanotechnology enabled products.

19 Nov 2010

CINJ experts to comment on importance of blood donation

Every two seconds, there is someone in the United States in need of blood. According to the American Red Cross, 65 percent of the American population is eligible to donate blood, but only five percent actually do. In New Jersey only two and a half percent of eligible donors will donate, while nine out of ten New Jersey residents will need blood at least once in their lives.

19 Nov 2010

Experts formulate research related to psychological adjustment and traumatic brain injury

Five U.S. federal agencies recently cosponsored a set of expert work groups to formulate common data elements for research related to psychological adjustment and traumatic brain injury (TBI).

19 Nov 2010

Mouse study finds blocking GnT-V enzyme delays breast cancer growth

New University of Georgia research, published this week in the early online edition of the journal Proceedings of the National Academy of Sciences, has found that blocking the action of an enzyme called GnT-V significantly delays the onset and spread of tumors in mice with cancer very similar to many cases of human breast cancer.

19 Nov 2010

Genetic alterations may lead to thoracic aortic disease

19 Nov 2010

Cancer News and Research

Latest Cancer News and Research

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Cold Spring releases new series of laboratory manuals

Substance abuse treatment facilities offering nicotine replacement therapy increased by 6%: Report

AVEO's RON antibody shows anti-tumor activity in human cancer xenografts

Fifth gene defect, 47 DNA regions linked to thoracic aortic disease: Researchers

ZIOPHARM announces data on darinaparsin efficacy for solid tumors at EORTC-NCI-AACR Symposium

ImmunoGen presents positive data on IMGN388 anticancer compound at EORTC-NCI-AACR Symposium

Research suggests new therapeutic approach to prevent transplant rejection

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Threshold Pharmaceuticals announces results on TH-302 prodrug for cancers at EORTC-NCI-AACR Symposium

ACE-041 drug may provide new option to treat cancer

Personalised medicine could help develop effective treatments for serious diseases

DoD recommends funding for Synta's STA-9584 for prostate cancer study

International businessman donates $50,000 for SCCO cancer study

Caprini Risk Model helps predict VTE risk in patients undergoing plastic surgery

CNS-ASU book explores relationship between nanotechnology and equity

CINJ experts to comment on importance of blood donation

Experts formulate research related to psychological adjustment and traumatic brain injury

Mouse study finds blocking GnT-V enzyme delays breast cancer growth

Genetic alterations may lead to thoracic aortic disease

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

Newsletters you may be interested in